Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1993;87:144-151

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lai, C. P.
Right arrow Articles by Takeshita, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lai, C. P.
Right arrow Articles by Takeshita, A.

Circulation, Vol 87, 144-151, Copyright © 1993 by American Heart Association


ARTICLES

Beneficial effects of atrial natriuretic peptide on exercise-induced myocardial ischemia in patients with stable effort angina pectoris

CP Lai, K Egashira, H Tashiro, H Narabayashi, S Koyanagi, T Imaizumi and A Takeshita
Research Institute of Angiocardiology and Cardiovascular Clinic, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

BACKGROUND. It has been shown that atrial natriuretic peptide (ANP), an endogenous vasodilator, dilates coronary arteries and decreases coronary vascular resistance. The purpose of this study was to determine whether an intravenous administration of ANP attenuated exercise-induced myocardial ischemia in 14 patients with stable effort angina pectoris. METHODS AND RESULTS. The first 12 patients (patients 1- 12) who had exercise-induced ST segment depression underwent treadmill exercise testing and the last seven patients (patients 8-14) underwent the exercise 201Tl-single-photon emission computed tomography (SPECT) study while synthetic 28-amino acid alpha-human ANP (0.1 micrograms/kg per minute) or saline was intravenously infused in a double-blind, cross-over manner. The duration of exercise testing was the same during ANP and saline infusion, which was determined in preliminary exercise testings in each patient to cause a transient perfusion defect and/or ischemic ST segment depression. During saline infusion, all 12 patients developed exercise-induced ischemic ST segment depression, whereas no significant ST segment depression appeared during ANP infusion. Average ST segment depression during ANP infusion was significantly less (p < 0.01) than that during saline infusion (0.0 +/- 0.0 versus 0.2 +/- 0.1 mV, mean +/- SD). The averaged extent and severity scores assessed by 201Tl-SPECT were smaller (p < 0.05) during ANP infusion than during saline infusion (extent score: 0.22 +/- 0.20 versus 0.42 +/- 0.20; severity score: 18.77 +/- 23.45 versus 38.24 +/- 24.04, respectively). ANP decreased resting systolic blood pressure from 125 +/- 15 to 110 +/- 15 mm Hg (p < 0.01) but did not alter resting heart rate. At peak exercise, systolic blood pressure, heart rate, and the rate-pressure products did not differ during ANP and saline infusion. At peak exercise, plasma ANP increased from 98 +/- 45 to 4,383 +/- 2,782 pg/ml and cGMP increased from 3.6 +/- 1.7 to 34.5 +/- 16.1 pmol/ml during ANP infusion; values were significantly higher than those during saline infusion (from 96 +/- 42 to 133 +/- 66 pg/ml and from 3.4 +/- 1.8 to 4.6 +/- 1.8 pmol/ml, respectively). CONCLUSIONS. An intravenous administration of ANP attenuated exercise-induced myocardial ischemia in patients with stable effort angina pectoris. Although the mechanism by which ANP attenuated myocardial ischemia was not defined, increased myocardial perfusion to the ischemic region might be an important factor.


This article has been cited by other articles:


Home page
VASC ENDOVASCULAR SURGHome page
W. W. Zhang, N. W. Hasaniya, S. Premaratne, and J. J. McNamara
Atrial Natriuretic Peptide Protects Against Ischemia-Reperfusion Injury in Rabbit Hearts In Vivo
Vascular and Endovascular Surgery, June 1, 2008; 42(3): 263 - 267.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch
Therapeutic benefits of increasing natriuretic peptide levels
Cardiovasc Res, August 15, 2001; 51(3): 510 - 520.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Matsumoto, A. Wada, T. Tsutamoto, T. Omura, H. Yokohama, M. Ohnishi, I. Nakae, M. Takahashi, and M. Kinoshita
Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure
Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1935 - H1942.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
F. Valsson, S. Lundin, K. Kirno, T. Hedner, E. Houltz, Y. Saito, and S.-E. Ricksten
Atrial Natriuretic Peptide Attenuates Pacing-Induced Myocardial Ischemia During General Anesthesia in Patients with Coronary Artery Disease
Anesth. Analg., February 1, 1999; 88(2): 279 - 279.
[Abstract] [Full Text] [PDF]